The use of agents such as bevacizumab has recently been recognized as an important complicating factor in patients who have colonic stents placed for palliative reasons.
De otro lado, en pacientes con tratamiento paliativo, esta decisión está basada principalmente en la expectativa de vida después de poner el stent 15.